BHV 5000

Drug Profile

BHV 5000

Alternative Names: BHV-5000

Latest Information Update: 13 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer Biohaven Pharmaceutical Holding Company
  • Class
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rett syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurological disorders; Rett syndrome

Most Recent Events

  • 06 Jul 2017 BHV 5000 receives Orphan Drug status for Rett syndrome in USA
  • 06 Jul 2017 Biohaven plans a study for Rett syndrome in 2018
  • 06 Jul 2017 Updated pharmacodynamics data from a preclinical trial in rett syndrome released by Biohaven
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top